Pralsetinib is an anticancer agent indicated for the treatment of adults with non-small cell lung cancer (NSCLC), based on the presence of a specific gene fusion named RET. Pralsetinib is indicated for the treatment of adults with non-small cell lung cancer (NSCLC), based on the presence of a specific gene fusion named RET.<\/p>\n
Gavreto is a cancer medicine for treating adults with advanced non-small cell lung cancer caused by changes in a gene called RET (known as RET fusion-positive NSCLC) and who have not been treated with a RET inhibitor. Gavreto contains the active substance pralsetinib.<\/p>\n
To access pralsetinib capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n
Gavreto (pralsetinib) is a medication used for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and adults with advanced or metastatic thyroid cancer.<\/p>\n
Facts about pralsetinib-capsules<\/strong><\/p>\n Disease Indications-Lung Cancer, Thyroid Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “pralsetinib capsules\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Roche Registration Limited
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n